Patheon plans additional investment in Milton Park, UK unit

By Admin
Share
Leading provider of contract development and commercial manufacturing services company Patheon Inc has planned to make additional investment in its Mil...

Leading provider of contract development and commercial manufacturing services company Patheon Inc has planned to make additional investment in its Milton Park facility. Patheon is a dedicated pharmaceutical development services facility focused on early development projects.

The company currently provides proof-of-concept and first –in man development programs for oral dose forms. It also offers Quick to Clinic which provides clinical trial materials as fast as four months from receipt of active pharmaceutical ingredient.

The service has been structured to provide support to emerging pharmaceutical companies’ with promising molecules. With the first phase of additional investment to Patheon’s Milton Park facility, the company will be able to  expand on the early development capabilities currently being offered, including the introduction of the SoluPath program.

The purchase of the new HME screening tool and spray-drier will supplement existing technologies at Milton Park to provide the SoluPath™ service to emerging pharmaceutical companies with poorly soluble molecules.

Robin Platt, Senior Director, Operations for Milton Park, said, “The introduction of Solupath™ into Milton Park’s existing capabilities is an exciting addition to Patheon’s service offering in Europe.” said Robin Platt, Senior Director, Operations for Milton Park.

Patheon Inc is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry for a wide range of solid and sterile dosage forms. It provides highest quality products and services to 300 of the world’s leading pharmaceutical and biotechnology companies.

Share

Featured Articles

NTT & Olympus: World's First Cloud Endoscopy System

NTT and medical technology company Olympus put on a demonstration, showing the IOWN APN's low-latency capability, for the first cloud endoscopy system

Richter BioLogics' New Biopharmaceutical GMP Facility

Richter BioLogics GmbH & Co KG's a new biopharmaceutical GMP facility in Germany will boost production capabilities and local employment

GE HealthCare's Pilot Study Shows Value of Portrait Mobile

A pilot study from GE Healthcare has shown the value of Portrait Mobile Continuous Monitoring Solution, a leap in post-surgical monitoring efficiency

50% of Teens to be Affected by Myopia Globally by 2050

Telehealth & COVID-19

NVIDIA’s AI Insights for Diabetes Prevention with GluFormer

Technology & AI

Novo Nordisk's CagriSema Next Gen Weight-Loss Treatment

Medical Devices & Pharma